Novartis, Elan Sue IPC Over Generic Focalin XR

Law360, New York (March 30, 2011, 5:59 PM EDT) -- Novartis Pharma AG and Elan Corp. PLC slapped Intellipharmaceutics Corp. with patent infringement suits in New Jersey and Delaware on Friday over the company's efforts to market a generic version of hyperactivity disorder drug Focalin XR.

Elan's suit, filed in the U.S. District Court for the District of Delaware, targets IPC, Intellipharmaceutics Ltd. and Par Pharmaceuticals Inc. Novartis and Celgene Corp., meanwhile, filed suit in the U.S. District Court for the District of New Jersey, naming IPC as the sole defendant.

Focalin XR is manufactured for...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.